The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity
| Autor: | L Astner, Susanna Kumlien Georén, Zuzana Hassan, G Oberg, Mohamed Abdel-Rehim, Moustapha Hassan, Margareta Bielenstein, O Ringdén, P Ljungman, Christina Nilsson, Albert N. Békássy |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Adult
Graft Rejection Male medicine.medical_specialty Time Factors Cyclophosphamide Adolescent medicine.medical_treatment Gastroenterology Transplantation Autologous Pharmacokinetics Internal medicine Mucositis medicine Humans Transplantation Homologous Drug Interactions Child Busulfan Bone Marrow Transplantation Transplantation Chemotherapy business.industry Hematology Total body irradiation Middle Aged medicine.disease Surgery Toxicity Drug Therapy Combination Female business Immunosuppressive Agents medicine.drug |
| Zdroj: | Karolinska Institutet Scopus-Elsevier |
| ISSN: | 0268-3369 |
| Popis: | Busulphan and cyclophosphamide (Bu/CP) are widely used in preparative regimens for bone marrow transplantation. Many studies have shown a wide variation in busulphan pharmacokinetics. Moreover, higher rates of liver toxicity were reported in Bu/CP protocols than in a total body irradiation (TBI)-containing regimen. In the present paper we investigated the effect of the time interval between the last dose of busulphan and the first dose of cyclophosphamide on the pharmacokinetics of CP and its cytotoxic metabolite 4-hydroperoxycyclophosphamide (4-OHCP). Thirty-six patients undergoing bone marrow transplantation (BMT) were included in the study. We also investigated the occurrence of veno-occlusive disease, mucositis and graft-versus-host disease. Ten patients conditioned with CP followed by TBI served as a control group (TBI). Twenty-six patients were conditioned with Bu/CP. The patients received Bu (1 mg/kg x 4 for 4 days), followed by CP (60 mg/kg for 2 days) administered as a 1-h infusion. Patients received their CP therapy either 7-15 h (group A, n = 12) or 24-50 h (group B, n = 14) after the last dose of Bu. None of the patients were given phenytoin or any other drug known to enhance CP metabolism. The administration of CP less than 24 h after the last dose of Bu resulted in: (1) a significantly (P = 0.003) lower clearance for cyclophosphamide was observed in group A (0.036 l/h/kg) compared to 0.055 and 0.055 l/h/kg, in the B and TBI groups, respectively; (2) significantly (P = 0.002) longer elimination half-life in group A (10.93 h) than in groups B and TBI (6.87 and 7.52 h, respectively); (3) significantly (P < 0.001) lower exposure to the cytotoxic metabolite (4-OHCP), expressed as the ratio AUC4-OHCP/AUCCP, in group A (0.0053) than that obtained in group B (0.013) and group TBI (0.012); (4) the patients in group A had a significantly (P < 0.05) higher incidence of VOD (seven of 12) than the other groups, B and TBI (2/14 and 1/10, respectively); and (5) mucositis was significantly higher in group A patients (8/12), being seen in only one patient in group B and none in the TBI group. The present study has shown that the interval between busulphan and cyclophosphamide administration can negatively affect the pharmacokinetics of cyclophosphamide and its cytotoxic metabolite. We conclude that the timing of CP administration must be considered in order to improve drug efficacy and reduce conditioning-related toxicity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|